pharma news today glp-1 2025 Novo cuts prices 70%, but semaglutide revenue could grow in 2026 GLP-1 Market Trends and Global

He notes that while weight loss medication is "appropriate for some patients," it is not suitable for allwith the GLP-1 being recommended on a case-by-case basis

A simplified graphic demonstrating the differences between endogenous and exogenous GLP-1

They're looking for real food that happens to work for them

A study of adults with diabetes suggests patients with obstructive sleep apnea derive a 20% greater mortality reduction from GLP-1 therapy than those without the sleep disorder.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for diabetes and obesity, exhibit pleiotropic effectsincluding anti-inflammatory, antioxidant, and neuroprotective propertiesthat position them as transformative candidates ...